Market News & Trends
Mayne Pharma Acquires Portfolio From Teva & Allergan
Mayne Pharma has recently completed its $652-million transaction with Teva and Allergan, taking ownership of 37 approved and five filed generic pharmaceutical products. This transaction…
Catalent Biologics & Zumutor Collaborate to Develop Antibodies With Enhanced ADCC Activity
Catalent Pharma Solutions and Zumutor Biologics Inc. recently announced a successful research study, combining Catalent’s proprietary GPEx technology and Zumutor’s fucose knockout platform, to create…
Abeona Therapeutics Uses Next-Generation AAV-Based Gene Therapy
Adeno-Associated Virus (AAV) vectors are currently among the most frequently used viral vectors for gene therapy. At recent meetings of the American Society for Gene…
Top Three Therapy Areas Account for 68% of Overall Pharmaceutical Industry Pipeline
The top three therapy areas – namely oncology, infectious diseases, and central nervous system (CNS) disorders – accounted for a combined 68% of the overall…
Top Three Therapy Areas Account for 68% of Overall Pharmaceutical Industry Pipeline
The top three therapy areas – namely oncology, infectious diseases, and central nervous system (CNS) disorders – accounted for a combined 68% of the overall…
Mayne Pharma Receives FDA Approval; Acquires Portfolio From Teva & Allergan
Mayne Pharma Inc. has received approval from the US FDA to market dofetilide capsules, a generic alternative to Tikosyn, an anti-arrhythmic agent used to treat…
MilliporeSigma Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables
Allows for more precise control of release kinetics Enables development of drugs requiring fewer injections for enhanced patient comfort and compliance Billerica, Massachusetts, July 12,…
Mayne Pharma Receives FDA Approval; Acquires Portfolio From Teva & Allergan
Mayne Pharma Inc. has received approval from the US FDA to market dofetilide capsules, a generic alternative to Tikosyn, an anti-arrhythmic agent used to treat…
MilliporeSigma Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables
Allows for more precise control of release kinetics Enables development of drugs requiring fewer injections for enhanced patient comfort and compliance Billerica, Massachusetts, July 12,…
Biogen & AbbVie’s Once-Monthly ZINBRYTA Approved in European Union
The European Commission (EC) has granted marketing authorization for ZINBRYTA (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), Biogen…
Intrexon & ZIOPHARM Amend Exclusive Channel Collaborations
Intrexon Corporation and ZIOPHARM Oncology, Inc. recently announced amendments to their Exclusive Channel Collaborations (ECCs) in the fields of oncology and graft-versus-host-disease (GvHD) to improve…
Intra-Cellular Therapies Reports Completion of Enrollment of Phase III Clinical Trial
Intra-Cellular Therapies, Inc. recently announced completion of enrollment in the second Phase III clinical trial (ITI-007-302) of the company's lead product candidate ITI-007 for the…
ICON to Acquire Clinical Research Management
ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries, recently announced it has agreed, subject…
Owen Mumford Unveils New Self-Injection Pen
Owen Mumford, a global industry leader in medical device design and manufacturing, recently unveiled a new addition to its range of medical devices, Ovaleap Pen.…
West’s SmartDose(®) Drug Delivery Technology Platform Selected by Amgen for Pushtronex™ System
On-body Infusor with Prefilled Cartridge to Deliver Monthly Single Dose of Repatha® (evolocumab) West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in…
Ligand Receives $4 Million From Expansion of Two OmniAb License Agreements
Ligand Pharmaceuticals Incorporated recently announced that two recent events relating to its OmniAb platform generated $4 million in combined payments due to Ligand. One event…
Cytokinetics Announces Start of Phase II Clinical Trial
Cytokinetics, Inc. recently announced the start of a randomized, double-blind, placebo-controlled, two-period crossover clinical trial designed to assess the effect of CK-2127107 (CK-107) on physical…
GeoVax Labs Announces Filing of IND Application for HIV Human Clinical Trial
GeoVax Labs, Inc. recently announced the filing of an Investigational New Drug (IND) application with the US FDA for the conduct of the next human…
CordenPharma Enters Oligonucleotide API Manufacturing Market to Further Strengthen CDMO Offering
CordenPharma recently announced its expansion into the oligonucleotide Active Pharmaceutical Ingredient (API) development and manufacturing market. Dr. Christian Ewers, Vice President Operations, CordenPharma, indicated the…
LEO Pharma Enters Biologics Through Strategic Partnership With AstraZeneca
LEO Pharma recently announced it is a significant step closer to realizing its vision of becoming the preferred dermatology care partner following a strategic partnership…























